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Abstract
Background: BRCA1 mutated breast cancers are commonly diagnosed as negative for classical hormone receptors
i.e. estrogen receptor, progesterone receptor and/or Her2. Due to these common targets being absent the
application of anti-endocrine therapies is rather limited and a certain focus has been set on discovering alternative
target molecules. We recently highlighted thyroid hormone receptors (TRs) to predict prognosis in breast cancer
patients that had been diagnosed a BRCA1 germline mutation. Vitamin D Receptor (VDR), Retinoid X Receptor (RXR)
and Peroxisome Proliferator-activated Receptor γ (PPARγ) are known to interact with TRs by forming functional
heterodimers. Whether VDR, RXR or PPARγ are expressed in BRCA1 mutated breast cancer or may even be present
in case of triple negativity is not known. Hence the current study aimed to investigate VDR, RXR and PPARγ in
BRCA1mut breast cancer and to test whether any of the three may be associated with clinico-pathological criteria
including overall survival.
Methods: This study analyzed VDR, RXR and PPARγ by immunohistochemistry in BRCA1 associated (n = 38) and
sporadic breast cancer (n = 79). Receptors were quantified by applying an established scoring system (IR-score)
and were tested for association with clinico-pathological variables.
Results: VDR, RXR and PPARγ were detected in over 90% of triple negative BRCA1mut breast cancer and were
significantly (VDR: p < 0.001, RXR: p = 0.010, PPARγ: p < 0.001) overexpressed in BRCA1 mutated as compared to
sporadic cancer cases. VDR and RXR positivity predicted prolonged overall survival only in BRCA1 mutated cases
while such association was not observed in sporadic breast cancer.
Conclusions: In conclusion, this is the first study to describe VDR, RXR and PPARγ in BRCA1 mutated breast cancer. Based
on the data presented here these receptors may be hypothesized to potentially evolve as interesting markers or even
targets in hereditary breast cancer. However, independent studies are indispensable thus to confirm this hypothesis.
Keywords: Vitamin D Receptor (VDR), Retinoid X Receptor (RXR), Peroxisome-proliferator activated Receptor γ (PPARγ),
Hereditary breast cancer, Survival, BRCA1
* Correspondence: sabine.heublein@med.uni-heidelberg.de
1Department of Obstetrics and Gynaecology - National Center for Tumor
Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
2Department of Obstetrics and Gynecology, Ludwig-Maximilians-University of
Munich, Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heublein et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:57 
DOI 10.1186/s13046-017-0517-1
Background
Immunoreactivity of estrogen receptor (ER), progester-
one receptor (PR) or Her2 in breast cancer tissue pro-
vides both predictive and prognostic information.
Determination of ER, PR and Her2 has evolved to be
mandatory during routine clinical management of breast
cancer patients. In general, about two third of breast
cancer cases are regarded to express at least ER on
immunohistochemistry level [1, 2] making them particu-
larly predestined for anti-endocrine treatment options.
On the other hand treatment of those breast cancers
being negative for ER, PR or Her2 is considered to be ra-
ther challenging. At least partly this may also be caused
by the fact that due to the lack of hormone receptors
anti-endocrine treatments options do not apply. Hence
this group of ER negative or even triple negative (i.e.
negative for ER, PR and Her2) breast cancers has
attracted extensive attention during the last years [3].
While treatment options in Her2 positive breast cancer
have notably improved since the approval of Her2
targeted agents [4], clinical management of triple nega-
tive breast cancer remains to be rather challenging [5].
Especially those patients that have been identified to
carry a germ line mutation in BRCA1 are diagnosed as
negative for ER, PR or Her2 to an unusually high extend
[6]. Since the frequent lack of hormone receptors (ER/PR)
or Her2 extensively narrows the application of (anti-)
endocrine therapies, BRCA1 associated breast cancers re-
quire a specially tailored therapeutic regimen [7]. As a
consequence the search for alternative predictive/prognos-
tic biomarkers is on the increase.
Like ER or PR, which have also been referred to as ‘clas-
sical steroid hormone receptors’, Vitamin D Receptor (VDR),
Retinoid X Receptor (RXR), Peroxisome Proliferator-
activated Receptor γ (PPARγ) and Thyroid Hormone Recep-
tors (TRs) are members of the nuclear hormone receptor
superfamily. There are several lines of evidence that VDR,
RXR or PPARγ may be of relevance in breast cancer tumor-
biology. First, TRs are known to assemble with VDR, RXR
and PPARγ by forming functional heterodimers. We
recently highlighted thyroid hormone receptors (TRs) to be
widely expressed in breast cancer tissue deriving from
patients diagnosed with a BRCA1 germline mutation. TRs
were of opposing prognostic significance and silencing of
TRalpha appeared to diminish viability of BRCA1 mutated
breast cancer cells [8]. Further, polymorphisms in VDR have
been demonstrated to be associated with breast cancer risk
[9] and both RXR and PPARγ have been demonstrated to
comprise anti-cancer cell activity [10–12].
However, neither VDR nor RXR nor PPARγ have been
studied in BRCA1 associated breast cancer so far. As
VDR, RXR and PPARγ can be quantified in cancer tissue
easily, they - given them being present in BRCA1 mutated
breast cancer cases at all - may evolve as novel alternative
biomarkers, especially for hormone receptor negative or
even triple negative breast cancer patients.
Methods
Aim of the study
Aim of the current study was to investigate whether VDR,
RXR and PPARγ in BRCA1mut are expressed in breast can-
cer tissue and whether any of the three may be associated
with clinico-pathological criteria including overall survival.
Patients
One hundred twenty-four patients diagnosed with sporadic
(n = 86) or BRCA1 associated cancer (n = 38) of the breast
were analyzed retrospectively in the current study. Patients
had undergone breast cancer surgery at the Department of
Obstetrics and Gynecology of the Ludwig-Maximilians-
University of Munich, Germany between 1987 and 2009.
Following resection breast cancer tissue underwent forma-
lin fixation and paraffin embedding. Formalin fixed paraffin
embedded (FFPE) tissue used in this study had been stored
under standardized conditions. Thyroid hormone receptor
profiling on the same patient panel has already been pub-
lished [8]. Seven cases were no longer available and hence
VDR, RXR and PPARγ staining was only performed in 79
sporadic and 38 BRCA1mut samples. Except from correl-
ation analysis (Table 4), calculations were done on this
slightly reduce panel on which VDR, RXR and PPARγ data
were available (n = 117). Breast cancer of non-specific type
(NST) was diagnosed in 91 (91/117, 77.8%) of the patients
and 62.1% (72/116) were graded as high grade (G3). A sig-
nificant fraction of the study sample was staged higher than
pT1 (n = 73, 62.4%) or presented with lymph node (n = 62,
56.4%) or distant metastasis (n = 49, 46.2%) at time of initial
diagnosis. Sufficient information thus to conclude on breast
cancer subtypes (Luminal A (n = 15), Luminal B (n = 14),
Her2 positive (n = 25), triple negative (n = 18)) was available
in 72 cases. Mean age (± STDV) of the cohort was 49.8 ±
13.4 years (BRCA1 associated cases: 41.9 ± 10.8 years; spor-
adic breast cancer: 53.6 ± 12.9 years). See Table 1 for further
details.
Study design
Patients’ data used within the current study were retrieved
from patients’ charts, from the Munich Cancer Registry
and by direct contact in a retrospective manner. Benign
tumors of the breast or patients diagnosed for in situ
carcinoma were excluded. The outcome assessed was
patients’ overall survival. Overall mean survival of the
cohort was 7.31 years (95% CI: 6.24 - 8.38 years) and mean
follow up time was 6.82 years (95% CI: 5.90 - 7.75 years).
Mean follow up time for all patients still alive at time of
analysis was 5.26 years.
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Assay methods
Mutation screening
Mutation analysis was described by Fischer et al. [13] and
was performed at a German center for BRCA1 mutation
testing (Technical University of Munich, Munich,
Germany) according to a standardized protocol. Briefly,
high performance liquid chromatography (dHPLC) and
sequencing of conspicuous amplicons was employed thus
to analyze PCR products comprising all coding exons of
BRCA1. Alternatively, direct sequencing of all BRCA1
amplicons was performed. The NCBI (National Center for
Biotechnology Information) cDNA sequence U14680.1
(BRCA1) served as a reference. In case of a negative
sequencing results multiplex ligation-dependent probe
amplification (MLPA) was used to screen for deletions or
duplications in BRCA1. Variants of unknown significance
(VUS) characterized as VUS Class III were not considered
as mutations.
Immunostaining
Immunohistochemistry of VDR, RXR and PPARγ on FFPE
sections had been described by our group [14, 15]. In
brief, antibodies detecting VDR (mouse anti human VDR,
monoclonal, AbD Serotec, Oxford, UK), RXR (mouse anti
human RXR, monoclonal, Perseus Proteomics Inc., Tokyo,
Japan) and PPARγ (rabbit anti human RXR, polyclonal,
Abcam, Cambridge, MA, USA) were stained by employing
standardized procedures and commercially available kits
(Vectastain Elite mouse-IgG-Kit for VDR, RXR staining;
ZytoChem Plus HRP Polymer System (Mouse/Rabbit) for
detection of PPARγ). Placenta tissue which had been
demonstrated to express VDR, RXR as well as PPARγ
served as positive control [14]. Placenta and breast cancer
sections treated with pre-immune rabbit IgG (supersensi-
tive rabbit negative control, BioGenex, Fremont, CA) or
isotype matched mouse IgGs (Dako, Hamburg, D) instead
of the primary antibody were used as negative controls.
Positive and negative controls were included in each
experiment. A well-established semiquantitaive scoring
system (IR-score or Remmele score) was employed thus
to quantify immunostaining in a semi-quantitative man-
ner [14, 16–18]. Scoring was performed by two independ-
ent observers by consensus. This scoring method has
already been proven suitable to assess VDR, RXR and
Table 1 Patient characteristics, whole study panel
[IRS] BRCA1mut sporadic
BRCA1mut sporad. VDR RXR PPARγ VDR RXR PPARγ
p <4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p
suptype other 8 18 ns 3 5 ns 1 7 ns 4 2 ns 11 6 ns 11 7 ns 16 2 ns
NST 30 61 4 25 11 19 12 8 40 21 30 31 55 6
G G1-2 8 36 0.015 2 5 ns 2 6 ns 4 3 ns 30 6 0.004 17 19 ns 35 1 ns
G3 29 43 5 24 10 19 12 7 21 21 24 19 36 7
pT pT1a-c 21 23 0.008 3 17 ns 4 17 ns 9 5 ns 14 9 ns 9 14 ns 19 4 ns
pT2-pT4 17 56 4 13 8 9 7 5 37 18 32 24 52 4
pN pN0 20 28 ns 2 18 ns 4 16 ns 9 5 ns 16 11 ns 14 14 ns 22 6 0.046
pN+ 15 47 5 10 7 8 6 4 31 16 23 24 45 2
pM pM0 18 21 ns 4 13 ns 4 14 ns 5 6 ns 8 12 0.031 8 13 ns 18 3 ns
pM+ 18 49 3 15 8 10 10 4 34 15 27 22 44 5
ER negative 27 24 0.002 6 20 ns 8 19 ns 9 9 ns 12 11 ns 15 9 ns 18 6 0.044
positive 11 40 1 10 4 7 7 1 28 12 20 20 38 2
PR negative 27 23 0.001 4 22 ns 8 19 ns 9 9 ns 14 8 ns 15 8 ns 18 5 ns
positive 11 41 3 8 4 7 7 1 26 15 20 21 38 3
Her2 negative 22 25 ns 3 18 ns 5 17 ns 9 8 ns 17 7 ns 12 13 ns 22 3 ns
positive 6 19 1 5 3 3 4 1 9 10 9 10 17 2
Triple-
negative
no 17 51 0.002 4 13 ns 7 10 ns 11 2 0.007 32 19 ns 25 26 ns 48 3 0.012
yes 12 6 0 11 2 10 2 7 4 1 3 3 3 3
Ki67 low 10 50 ns 4 5 ns 4 6 ns 6 4 ns 32 18 ns 29 21 ns 45 5 ns
high 10 20 2 8 4 6 6 3 13 6 9 11 17 3
age ≤41.5 y 19 16 0.002 3 15 ns 4 15 ns 4 6 ns 8 8 ns 6 10 ns 15 1 ns
>41.5 y 19 62 4 15 8 11 12 4 42 19 34 28 55 7
ns not significant
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PPARγ immunostaining [15–17]. The IR-score quantifies
immunoreactivity by multiplication of staining intensity
(graded as 0: none, 1: weak, 2: moderate and 3: strong
staining) and percentage of positively stained cells (0: no
staining, 1: ≤ 10% of the cells, 2: 11–50% of the cells, 3:
51–80% of the cells and 4: ≥ 81% of the cells). Tissue
samples that had been assigned an IR-Score higher or
equal to IRS 4 (i.e. IRS 4, IRS 6, IRS 8, IRS 9, IRS 12) were
scored as positive. This cut-off was set based on mean
expression of VDR (mean IRS [n = 117] = 4.14) and RXR
(mean IRS [n = 117] = 4.28).
Assessment of Her2 has been described in [19]. Her2
staining of cases that had been diagnosed before routine
HER2 staining was performed, was done on archived FFPE
samples where available. Thus to conclude on breast cancer
subtypes, we also performed Ki67 staining. Samples were
stained using an anti-Ki67 monoclonal antibody (Dako,
Hamburg, Germany) at a dilution of 1:150 on a VEN-
TANA®-Benchmark Unit (Roche, Mannheim, Germany).
Scoring was performed according to our local standards also
applying for routine clinical diagnostics: score 0 = 0% positive
cells, score 1: < 5% positive cells, score 2: < 10% positive cells,
score 3: < 20% positive cells, score 4: > 20% positive cells).
Tissue samples that had been assigned a Ki67-Score higher
than score 2 (i.e. score 3 or 4) were scored as positive. Over-
expression of Ki67 was defined as Ki67-Score 4.
Statistical analysis methods
This study has been carried out according to the REMARK
(Reporting Recommendations for Tumor Marker Prognos-
tic Studies) criteria [20]. The IBM statistic package SPSS
(version 23) was used to test data for statistical significance.
Fisher’s exact test and the Mann–Whitney test were used
thus to test differences for statistical significance. Survival
times were compared by Kaplan-Meier analysis and
differences in patient overall survival times were tested for
significance by using the chi-square statistics of the log rank
test.
Statistical analysis were also done in a group of 54 pa-
tients (n (sporadic) = 27, n (BRCA1 associated) = 27).
These patients had been matched (p = 1.000) according
to tumor size, lymph node status, presence of metastasis
and tumor grade.
Results
Study cohort
There was no significant difference in terms of histologic
subtype, presence of lymph node or distant metastasis or
Her2 positivity when sporadic cancer cases and those carry-
ing a BRCA1 germline mutation were compared. BRCA1mut
cases were smaller in size (p = 0.008), less well differentiated
(p = 0.015) and more often classified as negative for ‘classical’
hormone receptors (ER: p = 0.002; PR: p = 0.001) as
compared to sporadic cancers. In line with this, BRCA1mut
cancers were more often found to be triple negative (p =
0.002). Finally, BRCA1mut patients were significantly younger
(p = 0.002) at the time of primary diagnosis (Table 1).
VDR, RXR and PPARγ are overexpressed in BRCA1mut
breast cancer cases
VDR and RXR were expressed with a prominent nuclear
pattern, while PPARγ staining was mainly located in the
cytoplasm (Fig. 1). In case of all the three antigens staining
was found restricted to cancer cells whereas stroma tissue
and intercellular spaces stained negative. Regarding the
total patient sample both VDR and RXR were expressed in
about half of all cases (VDR: 57/115, 49.6%; RXR: 64/117,
54.7%) while much less cases were detected to stain positive
for PPARγ (PPARγ: 18/105, 17.1%). Apart from PPARγ
overexpression in triple negative cancers (p = 0.007) no
Fig. 1 VDR, RXR and PPARγ immunostaining in BRCA1 mutated breast cancer. VDR, RXR and PPARγ were detected by immunohistochemistry in
BRCA1 mutated breast cancer. Representative images are shown; magnification: a-c: 10 × lens, d-f: 25 × lens
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correlation of clinico-pathological parameters and VDR,
RXR or PPARγ positivity was detected in BRCA1mut pa-
tients (Table 1). In terms of sporadic cancer VDR was
overexpressed in poorly differentiated (p = 0.004) or non-
metastasized (M0, p = 0.031) cases. PPARγ was negatively
correlated with lymph node involvement (p = 0.046) and
ER staining (p = 0.044). Interestingly, PPARγ (p = 0.012)
was expressed in half of those sporadic cases that were
diagnosed as triple negative. No association of RXR and
clinico-pathological variables was detected in terms of
sporadic breast cancer. Patients carrying a BRCA1 germline
mutation overexpressed VDR (BRCA1mut vs. sporadic: IRS
6.00 vs. IRS 3.00%, p < 0.001), RXR (BRCA1mut vs. sporadic:
IRS 6.00 vs. IRS 3.00, p = 0.010) and PPARγ (BRCA1mut vs.
sporadic: IRS 2.00 vs. IRS 0.00, p < 0.001) when compared
to sporadic breast cancer (Fig. 2). A similar effect could be
reproduced when sporadic and BRCA1mut cancers were
compared with respect to breast cancer subtypes (Table 2).
BRCA1 mutation has been associated with the basal like
breast cancer subtype [21]. Among other criteria loss of
hormone receptors, loss of Her2, positivity for Ki67 and
poor differentiation have been identified to be characteris-
tics of basal like breast cancers [22, 23]. Our patient sam-
ple contained 18 TNBC cases with 14 of them being
classified as high grade. Information on Ki67 was available
in 13 of 18 TNBC cases. Information on both ki67 and
Grading was available in 13 cases. Seven of these 13
TNBC samples were identified as both high grade and
overexpressing Ki67, therefore comprising at least ‘basic
basal like’ features. Interestingly, 5 out of 7 (71%) BRCA1-
mut cases but only 2 out of 6 (33%) sporadic TNBC cases
showed highly proliferative i.e. ‘basic basal like’ character-
istics as explained above (Additional file 1: Figure S1).
VDR, RXR and PPARγ were expressed in 5 (VDR), 4
(RXR) and 3 (PPARγ) out of 5 highly proliferative BRCA1-
mut TNBC cases.
BRCA1mut breast cancer is commonly found to be nega-
tive for classical hormone receptors i.e. ER, PR and/or
Her2. We then analyzed expression of VDR, RXR and
PPARγ in those BRCA1mut cases that stained negative for
classical hormone receptors. Interestingly, the vast
majority of hormone receptor negative, BRCA1mut cases
were positive for VDR, RXR or PPARγ. In particular, triple
negative breast cancer stained positive in up to 100% of
the cases (Fig. 3).
Comparisons were repeated in the matched patient panel
(Table 3) and overexpression of nuclear receptors in BRCA1-
mut as compared to sporadic cancer cases could be repro-
duced in terms of VDR (BRCA1mut vs. sporadic: IRS 6.00 vs.
IRS 3.50 p = 0.008) as well as PPARγ (BRCA1mut vs. sporadic:
IRS 6.00 vs. IRS 4.00, p = 0.008). Further, PPARγ remained to
be overexpressed in triple negative cancers regarding both
BRCA1mut (p = 0.036) and sporadic (p= 0.040) cases. Further,
PPARγ was positively correlated to pN0 (p = 0.047) in
sporadic cancers. A positive correlation of RXR and PR (p =
0.008) was observed. Finally, RXR and VDR were found to
be inversely correlated to grading (RXR - grading: p = 0.022)
or presence of distant metastasis (VDR - pM: p= 0.041).
Correlation analysis
Nuclear hormone receptors are known to act as heterodi-
mers. Thus to conclude on potential heterodimerization
correlation analysis was performed. Several correlations
among VDR, RXR and PPARγ among each other were ob-
served both in BRCA1mut and sporadic cases (Table 4).
Interestingly, RXR (BRCA1mut: p = 0.014) and PPARγ
(sporadic: p = 0.035) immunoreactivity was found to rise
Fig. 2 VDR, RXR and PPARγ are significantly up-regulated in BRCA1 mutated breast cancer tissue. VDR, RXR and PPARγ immunoreactivity of
sporadic vs. BRCA1 mutated breast cancer tissue was compared. All the three receptors were found to be significantly up-regulated in a BRCA1
mutated genetic background. P-values derived from relevant Mann–Whitney-U tests are shown
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in parallel to TRβ positivity, while no correlation to onco-
genic TRα was observed.
Absence of VDR or RXR is associated with reduced overall
survival in BRCA1mut cases
VDR, RXR and PPARγ were correlated to patients’ overall
survival (OS). Studying the whole patient sample OS of
those cases that stained negative for either VDR (95% CI
(VDR negative): 4.43 y - 7.14 y; 95% CI (VDR positive):
7.39 y - 10.7 y; p = 0.004, Fig. 4a) or RXR (95% CI (RXR
negative): 4.37 y - 7.47 y; 95% CI (RXR positive): 6.90 y -
9.72 y; p = 0.009, Fig. 4b) was found to be significantly
reduced. However, no statistical association to OS was
detected in case of sporadic cancer cases (Fig. 4g-i). Nega-
tivity for either VDR (95% CI (VDR negative): 0.69 y -
9.38 y; 95% CI (VDR positive): 10.3 y - 13.4 y; p = 0.019,
Fig. 4d) or RXR (95% CI (RXR negative): 3.92 y - 11.3 y;
95% CI (RXR positive): 10.1 y - 12.2 y; p = 0.007, Fig. 4e)
was associated with significantly shortened overall survival
in those cases that had been diagnosed a BRCA1 germline
mutation. PPARγ was not related to OS at all (Fig 4c, f, i).
Thus to avoid confounding effects survival analysis were
repeated in those patients that had been matched for
clinico-pathological variables. Interestingly, both VDR (95%
CI (VDR negative): 2.47 y - 5.67 y; 95% CI (VDR positive):
9.61 y - 12.9 y; p < 0.001, Fig. 5a) and RXR (95% CI (RXR
negative): 3.23 y - 8.52 y; 95% CI (RXR positive): 6.80 y -
10.8 y; p = 0.005, Fig. 5b) positivity predicted favorable OS
in the matched patient panel prior to stratification.
Following stratification this only remained to be significant
in those patients that had been diagnosed a germline muta-
tion in BRCA1 (95% CI (VDR negative): 0.69 y - 9.38 y;
95% CI (VDR positive): 9.98 y - 13.7 y; p = 0.047, Fig. 5d;
95% CI (RXR negative): 2.98 y - 10.8 y; 95% CI (RXR posi-
tive): 10.1 y - 12.6 y; p = 0.008, Fig. 5e). Again, no associ-
ation of PPARγ and OS was observed (Fig. 5c, f, i).
Discussion
VDR, RXR and PPARγ overexpression in BRCA1mut breast
cancer
To the best of our knowledge this analysis is among the
first to show immunopositivity of VDR, RXR and PPARγ in
BRCA1mut breast cancer patients. There is some evidence
that absence of functional BRCA may alter expression of
these so called ‘thyroid hormone receptor like genes’. For
instance, knockdown of BRCA2 in breast cancer cell lines
modulated expression of RXR isoforms in opposing ways
and knockout of BRCA1 reduced expression of PPARγ in
cardiomyocytes [24, 25]. Some authors even reported a
physical interaction of VDR and BRCA1 protein [26, 27].
Hence, loss of functional BRCA1may lead to compensatory
up-regulation of VDR. Whether a scenario like this may
explain overexpression of VDR in BRCA1mut breast cancer
cases remains to be elucidated. E3 Ubiquitin ligase activity
of functional BRCA1 may serve as an alternative way to in-
terpret overexpression of thyroid like receptors in a BRCA1
mutant genetic background. Wildtype BRCA1 protein
contributes to degradation of nuclear hormone receptors
Table 2 VDR, RXR and PPARγ immunopositivity in breast cancer subgroups
VDR (median IRS) RXR (median IRS) PPARγ (median IRS)
BRCA1mut sporadic p BRCA1mut sporadic p BRCA1mut sporadic p
Luminal A 3,5 1,0 0,142 6,0 4,0 0,223 1,5 0,0 0,002
Luminal B 8,0 3,5 0,026 6,0 3,5 0,23 1,0 0,0 0,032
Her2 positive 8,0 4,0 0,023 4,5 4,0 0,769 1,0 0,0 0,061
TNBC 8,0 3,0 0,003 8,0 2,5 0,036 6,0 2,0 0,072
Median VDR, RXR and PPARγ immunopositivity was analyzed in breast cancer subtypes.
Fig. 3 Percentages of VDR, RXR and PPARγ cases in respect to hormone receptor expression. VDR, RXR and PPARγ positive cases in ER negative,
PR negative, Her2 negative and triple negative cancer were counted and are displayed as percentage in respect to the respective hormone
receptor profile. Even in absence of classical hormone receptors VDR, RXR or PPARγ were detected in the large majority of cases
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Table 3 Patient characteristics, matched groups
[IRS] BRCA1mut sporadic
VDR RXR PPARγ VDR RXR PPARγ
<4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p <4 ≥4 p
suptype other 3 2 ns 1 4 ns 4 0 ns 2 3 ns 3 3 ns 5 1 ns
NST 4 18 9 13 9 7 11 10 8 13 17 4
G G1-2 2 5 ns 2 5 ns 4 2 ns 5 2 ns 0 7 0.022 7 0 ns
G3 5 15 8 12 9 5 8 11 11 9 15 5
pT pT1a-c 3 9 ns 3 9 ns 8 2 ns 4 8 ns 5 7 ns 9 3 ns
pT2-pT4 4 11 7 8 5 5 9 5 6 9 13 2
pN pN0 2 13 ns 3 12 ns 8 4 ns 6 8 ns 7 8 ns 10 5 0.047
pN+ 5 7 7 5 5 3 7 5 4 8 12 0
pM pM0 4 7 ns 3 8 ns 4 3 ns 2 8 0.041 3 8 ns 10 1 ns
pM+ 3 13 7 9 9 4 11 5 8 8 12 4
ER negative 6 13 ns 7 12 ns 8 6 ns 8 8 ns 9 8 ns 12 5 ns
positive 1 7 3 5 5 1 5 5 2 8 10 0
PR negative 4 16 ns 7 13 ns 8 6 ns 9 6 ns 10 6 0.008 12 4 ns
positive 3 4 3 4 5 1 4 7 1 10 10 1
Her2 negative 3 13 ns 4 12 ns 8 5 ns 7 4 ns 4 8 ns 9 3 ns
positive 1 3 2 2 2 1 2 7 2 7 8 1
Triple-
negative
no 4 9 ns 6 7 ns 9 2 0.036 7 10 ns 4 13 ns 16 1 0.040
yes 0 8 1 7 1 4 4 1 3 3 3 3
Ki67 low 5 5 ns 6 4 ns 7 3 ns 8 9 ns 8 9 ns 13 4 ns
high 1 4 1 4 3 1 4 2 3 4 6 1
age ≤41.5 y 3 9 ns 4 8 ns 3 4 ns 1 3 ns 1 3 ns 4 0 ns
>41.5 y 4 11 6 9 10 3 12 10 10 13 18 5
ns not significant
Table 4 Correlation analysis
BRCA1mut sporadic
VDR RXR PPARγ TRα TRβ VDR RXR PPARγ TRα TRβ
Spearman's rho VDR cc 1.000 0.336 0.538 –.008 .191 1.000 .042 0.256 .028 .097
Sig. x .042* .005* .964 .257 x .718 .024* .810 .397
n 37 37 25 37 37 78 78 78 78 78
RXR cc 1.000 0.578 –.172 0.395 1.000 –0.325 –.031 .045
Sig. x .002* .302 .014* x .003* .786 .693
n 38 26 38 38 79 79 79 79
PPARγ cc 1.000 –.001 .241 1.000 –.063 0.237
Sig. x .997 .236 x .582 .035*
n 26 26 26 79 79 79
TRα cc 1.000 –.192 1.000 .195
Sig. x .248 x .071
n 38 38 86 86
TRβ cc 1.000 1.000
Sig. x x
n 38 86
Correlation analysis was performed in BRCA1mut as well as in sporadic cases. Significant correlations are indicated by asterisks (*: p < 0.05)
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including VDR, RXR and PPARγ via its ubiquitinilation and
sumoylation activity [28–31]. Thus loss of functional
BRCA1 may explain overexpression of these receptors in
BRCA1 mutant genetic background. A similar mechanism
was demonstrated in case of thyroid hormone receptors in
BRCA1mut breast cancer [8]. Besides carrying a BRCA
mutation, cancers expressing alternative nuclear hormone
receptors were often found to be triple negative. VDR, RXR
and PPARγ were even detected in those cancers character-
ized as both triple negative and highly proliferative - two
basic features of basal like breast cancer [22, 23].
Comprehensive analysis of “basal like biomarkers” per-
formed in a larger patient sample is mandatory thus to
properly select basal like breast cancer cases and to further
study the role of alternative hormone receptors in basal like
breast cancer.
VDR and RXR in BRCA1mut breast cancer - translational
aspects
Though several significant associations of VDR, RXR and
PPARγ to clinico-pathological variables were observed in
sporadic breast cancer, there was only one significant
Fig. 4 Immunopositivity of VDR and RXR predict favorable overall survival in BRCA1mut breast cancer. Survival analysis was performed on the
whole patient sample (n = 117, a-c) as well as on BRCA1mut (n = 38, d-f) and sporadic (n = 79, g-i) cancer cases
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correlation detected when VDR, RXR and PPARγ were cor-
related to clinico-pathological variables in BRCA1mut cases.
A comprehensive study on VDR in 1116 breast cancer pa-
tients revealed VDR to correlate to those clinic-pathological
variables that may indicate lower tumor-biologic aggressive-
ness [32]. We found that presence of VDR is positively cor-
related to the absence of distant metastasis. In line with
others [15, 33] this suggests that VDR expression may exert
differentiating effects on breast cancer cells. This is in
agreement with the fact that absence of VDR was corre-
lated with shortened OS of patients carrying a BRCA1
mutation in the current analysis. However results on
whether VDR may predict prognosis in breast cancer are
not consistent throughout the literature. While a former
study of our group detected VDR to correlate with favor-
able OS [16], others did not find an association of VDR and
breast cancer prognosis [32]. So far, no data on the prog-
nostic significance of VDR in BRCA1 mutated breast can-
cer have been published. Whether the association of VDR
and OS observed in the current work may be enhanced
due to the absence of wildtype BRCA1 remains to be vali-
dated in larger trials as well as on a functional level.
Fig. 5 Immunopositivity of VDR and RXR predict favorable overall survival in BRCA1mut breast cancer. Survival analysis was performed on the
matched patient sample (n = 54, a-c) as well as on BRCA1mut (n = 27, d-f) and sporadic (n = 27, g-i) cancer cases of the matched sample
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Strikingly, Thakkar et al. recently highlighted that VDR ag-
onists may inhibit proliferation of triple negative, VDR posi-
tive breast cancer cell lines in a receptor dependent manner
[34]. This observation further supports a tumor suppressor
like activity of VDR and may further strengthen a potential
role of VDR as a promising new target in triple negative
breast cancer.
There is some evidence that activation of RXR may induce
apoptosis in breast cancer cells and may reduce cell growth
[35, 36]. Even less is known on how RXR may affect tumor-
biologic characteristics on BRCA1mut breast cancer and no
data on prognostic significance of RXR in hereditary breast
cancer have been published so far. Our results presented
suggest that RXR positivity may predict favorable prognosis
in breast cancer. Whether BRCA1mut breast cancer may be
sensitive to RXR modulating drugs and whether this may
affect tumor biology or even clinical outcome remains to be
determined - with the same applying for VDR, respectively.
Conclusion
The present study demonstrated BRCA1mut breast cancer
cases to overexpress VDR, RXR and PPARγ - especially in
the absence of ‘classical’ hormone receptors. Further loss
of both VDR and RXR predicted shortened overall survival
in BRCA1mut breast cancer. Therefore VDR may act as a
tumor suppressor in presence of BRCA1mut and may
potentially evolve as a promising new target in the future.
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